DiagnaMed Holdings to Commercialize Virtual Reality Tech That Diagnoses Neurologic Disorders - Inside Precision Medicine

Credit: mikkelwilliam/Getty Images

Digital diagnostics institution DiagnaMed Holdings announced contiguous that it has acquired the exclusive worldwide licensing statement with the tech transportation corp of the University of Kansas for the improvement and commercialization of a caller virtual world (VR) and artificial quality (AI) neurodiagnostic strategy for the evaluation, diagnosis and monitoring of neurodegenerative diseases, specified arsenic Parkinson’s disease.

The system, dubbed VR/AI Neuro, has been successful improvement implicit the past respective years by Kansas University Medical Center, Osaka University and Augusta University and is designed for usage successful the objective mounting with applications successful telehealth. The exertion leverages VR goggles with an infrared camera embedded successful the lens and emulates a real-world situation and communal regular tasks to assistance measurement a patient’s quality to fixate connected a point, behaviour creaseless pursuit of an object, oregon execute saccades (rapid oculus movements betwixt 2 points). By measuring the oculus movements comparative to these tasks VR/AI Neuro’s exertion is plan to elicit the oculus movements commonly associated with neurodegenerative diseases specified arsenic abnormal saccades, quadrate question jerks, and ocular tremors.

The probe squad evaluated the instrumentality with 9 patients diagnosed with Parkinson’s illness and 7 steadfast controls to spot however it compared with existent objective diagnosis methods. Researchers past applied eye-tracking algorithms and representation enhancement to the oculus recordings collected ruing the valuation and conducted a abbreviated follow-up survey with 2 physicians for evaluation. Results showed that the VR/AI Neuro strategy interface could elicit 5 communal types of movements usable for evaluation, physicians could corroborate 3 retired of 4 abnormalities, and visualizations were rated arsenic perchance utile for diagnosis.

Early and close diagnosis remains a situation for neurodegenerative conditions. Evaluations tin beryllium time-consuming, patients indispensable often question agelong distances for successful bureau visits with specialists successful metropolitan areas oregon antithetic cities, and misdiagnosis tin effect successful improper treatment. The anticipation is that emerging technologies leveraging AI that tin way and emulate a patient’s regular tasks tin beryllium a new, and much accurate, instrumentality for the diagnosis of neurodegenerative diseases.

“We are excited to beforehand the improvement of a caller virtual world and artificial quality neurodiagnostic strategy that volition purpose to alteration the mode neurodegenerative diseases are diagnosed and managed,” said Fabio Chianelli, president of the committee of DiagnaMed. “We are focused connected processing and commercializing next-generation integer diagnostic tools for encephalon wellness successful intelligence wellness and neurological disorders. The VR/AI Neuro strategy complements our merchandise improvement programs.”

Other products successful the encephalon wellness portfolio of DiagnaMed see include BrainAGE and BrainTremor, for applications successful intelligence wellness and neurological disorders.

BrainAGE is an EEG-based machine-learning method for assessing whether an individual’s encephalon is aging much rapidly oregon much dilatory than is emblematic for steadfast individuals. Some people’s brains relation arsenic if older than their chronological age; different people’s brains relation arsenic if younger. BrainAGE provides a measurement of wide encephalon wellness by detecting the combined effects of physiological, pathological, genetic, environmental, and manner factors that impact the complaint astatine which a encephalon ages.

BrainTremor combines smartwatch exertion and EEG measurements to observe tremors, and measurement cognitive and encephalon enactment for Parkinson’s disease. It leverages an AI algorithm to assistance diagnose and negociate disease, areas of expanding involvement to researchers and clinicians.

DiagnaMed says its extremity is to implicit the improvement of a prototype of BrainAge and BrainTremor for objective research, with an oculus toward commercialization successful 2023.